Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease

Area of Science:

• Cardiology
• Nephrology
• Clinical Trials

Background:

• Limited research exists on early revascularization's impact on renal function in unstable coronary artery disease (CAD).
• Investigating the interplay between renal function and treatment strategies in CAD is crucial for patient outcomes.

Purpose of the Study:

• To evaluate the effect of early revascularization on renal function in patients with unstable CAD.
• To determine if an invasive strategy improves outcomes compared to a noninvasive approach in different renal function strata.

Main Methods:

• The Fast Revascularisation during InStability in Coronary artery disease (FRISC-II) trial randomized 2457 unstable CAD patients to noninvasive or invasive strategies.
• Patients were stratified by creatinine clearance (CrCl) tertiles (< 69, 69-90, > 90 mL/min) and followed for 2-year death/myocardial infarction (MI) rates.

Main Results:

• In the invasive group, death/MI rates were significantly reduced for CrCl < 69 mL/min (14.6% vs. 22.4%) and CrCl 69-90 mL/min (9.9% vs. 14.6%) compared to the noninvasive group.
• Reduced CrCl (< 69 mL/min) was an independent risk factor for adverse events in the noninvasive group (OR, 1.96), but not in the invasive group (OR, 1.09).
• An interaction between treatment strategy and CrCl < 90 mL/min was independently associated with future MI risk (P = .006).

Conclusions:

• An early invasive treatment strategy effectively reduces the long-term risk of death and MI in unstable CAD patients with mildly to moderately reduced renal function.
• The benefits of an invasive approach are most pronounced in patients with impaired creatinine clearance, suggesting renal function is a key factor in treatment decisions.